Pyoderma gangrenosum with lung involvement treated with infliximab

被引:7
作者
Deregnaucourt, D. [1 ]
Buche, S. [1 ]
Coopman, S. [2 ]
Basraoui, D. [3 ]
Turck, D. [2 ]
Delaporte, E. [1 ]
机构
[1] Univ Lille 2, CHRU Lille, Hop Claude Huriez, Serv Dermatol, F-59037 Lille, France
[2] Univ Lille 2, Hop Jeanne de Flandre, Dept Pediat, Unite Gastroenterol Hepatol & Nutr, F-59037 Lille, France
[3] Univ Lille 2, CHRU Lille, Hop Jeanne de Flandre, Serv Radiopediatrie, F-59037 Lille, France
来源
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE | 2013年 / 140卷 / 05期
关键词
Pyoderma gangrenosum; Infliximab; Ulcerative colitis; DISEASE; MANIFESTATIONS; THERAPY; PATIENT;
D O I
10.1016/j.annder.2013.01.428
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background.-Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis often associated with systemic diseases, particularly chronic inflammatory bowel diseases. Extracutaneous manifestations (articular, ocular, renal, pulmonary, hepatosplenic, muscular) exist, with lung involvement being the most common. Patient and methods.-We report a case of PG with skin and lung involvements in a patient treated with high-dose corticosteroids in a setting of severe ulcerative colitis (UC). Lung involvement was diagnosed during the pretreatment assessment performed prior to initiation of anti-TNF alpha therapy. Infliximab resulted in rapid improvement of the lung and skin lesions. Discussion.-In the event of simultaneous cutaneous PG lesions and lung lesions suggestive of abscess, visceral involvement should be suspected. First-line treatment consists of oral corticosteroids. In our patient, the occurrence of lesions under corticosteroids in UC militated in favour of anti-TNF alpha therapy, which proved effective. (C) 2013 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:363 / 366
页数:4
相关论文
共 24 条
[1]   Pyoderma gangrenosum: uncommon presentations [J].
Ahmadi, S ;
Powell, FC .
CLINICS IN DERMATOLOGY, 2005, 23 (06) :612-620
[2]  
Areias E, 1987, Med Cutan Ibero Lat Am, V15, P185
[3]   Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients [J].
Binus, A. M. ;
Qureshi, A. A. ;
Li, V. W. ;
Winterfield, L. S. .
BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (06) :1244-1250
[4]  
Brocq L, 1908, B MEM SOC MED HOP P, V25, P290
[5]   Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial [J].
Brooklyn, TN ;
Dunnill, MGS ;
Shetty, A ;
Bowden, JJ ;
Williams, JDL ;
Griffiths, CEM ;
Forbes, A ;
Greenwood, R ;
Probert, CS .
GUT, 2006, 55 (04) :505-509
[6]   Cavitating pulmonary infiltrate in an adolescent with pyoderma gangrenosum: A rarely recognized extracutaneous manifestation of a neutrophilic dermatosis [J].
Brown, TS ;
Marshall, GS ;
Callen, JP .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 43 (01) :108-112
[7]   Pyoderma (echthyma) gangrenosum - Clinical and experimental observations in five cases occurring in adults [J].
Brunsting, LA ;
Goeckerman, WH ;
O'Leary, PA .
ARCHIVES OF DERMATOLOGY AND SYPHILOLOGY, 1930, 22 (04) :655-680
[8]   Pyoderma gangrenosum: An update [J].
Callen, Jeffrey P. ;
Jackson, J. Mark .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2007, 33 (04) :787-+
[9]   Pulmonary manifestations of Pyoderma gangrenosum [J].
Chahine, Bachar ;
Chenivesse, Cecile ;
Tillie-Leblond, Isabelle ;
Delaporte, Emmanuel ;
Scherpereel, Arnaud ;
Grignet, Jean-Paul ;
Tonnel, Andre-Bernard .
PRESSE MEDICALE, 2007, 36 (10) :1395-1398
[10]  
Delbrel X, 2001, ANN MED INTERNE, V152, P65